The Searle Company Limited: PKR 4B Investment in Subsidiary Announced
Summary
Searle plans Rs 4B investment in Nextar to optimize product portfolio, pending shareholder and regulatory approvals.
Kind of disclosure: Expansion/Capex
Read the original filingKey facts
- Proposed Rs 4B investment in Nextar
- Rs 4B
- Nextar to be renamed Searle Biopharma
- Name change
- Regulatory approvals pending
- SECP approval required
- Shareholder approval required
- Extraordinary general meeting
- Board meeting held on May 11, 2026
- 2026-05-11
The Searle Company Limited (SEARL) on Nafa
Last price Rs 79.56 · Pharmaceuticals · You can own SEARL shares from your phone.
More SEARL announcements
- Material informationSearle Appoints New Chairman and CEOThe Searle Company Limited announces the appointment of Mr. Munis Abdullah as Chairman and re-appointment of Mr. Tahir Ahmed as CEO.
- NoticeSHORT NOTICE (EMERGENT) BOARD MEETING- OTHER THAN FINANCIAL RESULTS
- NoticeCredit of final cash dividend
- NoticeTransmission of Quarterly Financial Statements for the Period Ended 30/09/2026
- NoticeCERTIFIED TRUE COPY OF THE RESOLUTIONS PASSED AT THE 61ST ANNUAL GENERAL MEETING OF THE SEARLE COMPANY LIMITED
- Financial resultThe Searle Company Limited reported a net profit of Rs 1.20 billion for the quarter ended September 30, 2026Filed as: Financial Results for the Quarter Ended 2026-09-30
Source: The Searle Company Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.